Ghana today received 98,400 doses of Covid-19 Vaccine AstraZeneca that were donated by Norway through the COVAX facility.
COVAX is a global initiative co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi (the Vaccines Alliance) and the World Health Organization, which works with governments and manufacturers to accelerate the development, production and equitable access to Covid-19 vaccines around the world.
Country President for Africa, AstraZeneca, Barbara Nel, said: "I was delighted to see the arrival of 98,400 doses of the COVID-19 Vaccine AstraZeneca at Kotoka International Airport today.
"This donation from Norway will bolster Ghana’s vaccination programme and is wonderful news for the Ghanaian people.”
“Today’s arrival demonstrates the value of governments, industry and others working together to address our continent’s urgent needs to access vaccines.
"We will continue to advocate for equitable vaccine distribution and for more vaccines to get to Africa this year and into 2022. In this regard, AstraZeneca’s commitment to Africa remains steadfast,” she stated.
AstraZeneca was the first global pharmaceutical company to join COVAX in June 2020, and more than 113 million doses of the Company’s vaccine have been delivered through COVAX to date.
AstraZeneca is committed to supplying the vaccine broadly and equitably worldwide at no profit during the pandemic period.
To date, more than 1 billion doses of Covid-19 Vaccine AstraZeneca have been released for supply to over 170 countries around the world, and approximately two-thirds have gone to low- and lower-middle-income countries.
AstraZeneca is the third biggest supplier of Covid-19 vaccine doses in the world. Since the first international launch in early 2021, the vaccine has helped prevent hundreds of thousands of hospitalisations and helped save tens of thousands of lives.
Covid-19 Vaccine AstraZeneca
The Covid-19 Vaccine AstraZeneca (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech.
It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.
After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
Latest Stories
-
8 cringe-worthy signs you’re the other woman or one of many
4 mins -
Ho Technical University management denies knowledge of name-changing attempts
6 mins -
Global Cocoa Marketing Companies refuse to pay realistic Cocoa prices – CGCI
12 mins -
African Court delegation visits ECOWAS Court, strengthen cooperation
13 mins -
DVLA Management, Board embark on familiarisation tour of Volta, Oti
16 mins -
Is King Promise truly married or it’s just to promote a new song?
20 mins -
Today’s front pages: Wednesday, April 24, 2024
33 mins -
Shop attendant, 22, convicted for stealing over GH¢39k
40 mins -
African Games medalists cries over unpaid bonuses
45 mins -
The Plastic menace: Our environment, our survival
45 mins -
NDC petitions Speaker on missing BVDs at EC
50 mins -
Current dumsor not as bad as Mahama-era – Prof Stephen Adei
2 hours -
NDC officially out-doors Naana Jane as running mate today
3 hours -
SOEs should not compromise on ethical standards, accountability – Akufo-Addo
3 hours -
Man tells grieving wife she doesn’t need a mother’s day gift because she’s ‘no longer a mom’
4 hours